Pharmaceutical

Ji Xing acquires Biogen’s BIIB131 for acute ischemic stroke

Ji Xing Pharmaceuticals acquired Biogen’s BIIB131 for advancing worldwide clinical developments in treating acute ischemic stroke (AIS).

Jan 13, 2024 - 18:00
Ji Xing acquires Biogen’s BIIB131 for acute ischemic stroke
Ji Xing Pharmaceuticals acquired Biogen’s BIIB131 for advancing worldwide clinical developments in treating acute ischemic stroke (AIS).
Read the original article

Tags:

Previous Article

Dermavant maps out atopic dermatitis filing after positive Phase III data 

Next Article

ClinChoice enhances global reach with CSI Medical acquisition

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

A STAT analysis shows how top drug companies are starting to take action on climate

A STAT analysis shows how top drug companies are starti...

Sep 28, 2023

STAT+: FDA will allow troubled chemotherapy maker to resume distribution of cancer drugs in short supply

STAT+: FDA will allow troubled chemotherapy maker to re...

Jun 6, 2023

STAT+: Covid-19 burnished pharma’s reputation among patient groups, but access to medicines is now an issue

STAT+: Covid-19 burnished pharma’s reputation among pat...

Apr 29, 2023